GlassScriptPhysician profile
Katherine A Lewinski
NPI 1114108727
$1,216.46
in general payments reported to CMS, 2019-2025
25 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $444 · 2020: $633 · 2024: $14.60 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $139.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $210.39 | 2019-2020 | |
| Novo Nordisk INC | $158.94 | 2019-2020 | |
| Abbvie INC. | $96.38 | 2019-2024 | |
| Axsome Therapeutics, INC. | $61.95 | 2025 | Symbravo |
| Astrazeneca Pharmaceuticals LP | $58.06 | 2019-2020 | |
| Glaxosmithkline, LLC. | $55.87 | 2019-2025 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.78 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $45.83 | 2019-2020 | |
| Sanofi Pasteur INC. | $45.40 | 2025 | |
| Horizon Therapeutics Plc | $44.70 | 2020 | |
| Pfizer INC. | $44.38 | 2019 | |
| Esperion Therapeutics, INC. | $42.20 | 2020 | |
| Lilly USA, LLC | $39.19 | 2019 | |
| Amarin Pharma, INC. | $38.90 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $31.49 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $28.23 | 2019 | |
| Amneal Pharmaceuticals LLC | $24.57 | 2019 | |
| Bausch Health US, LLC | $19.92 | 2019 | |
| Arbor Pharmaceuticals, INC. | $19.62 | 2019 | |
| Janssen Pharmaceuticals, INC | $19.57 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $18.20 | 2019 | |
| Amgen INC. | $18.02 | 2020 | |
| Seqirus USA INC | $16.94 | 2019 | |
| Avion Pharmaceuticals | $13.97 | 2020 | |
| Hikma Pharmaceuticals USA | $12.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Lewinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.